News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AmpliMed Corporation To Present Positive Phase I Study Results For Amplimexon(R) (imexon for inj.) In Patients With Advanced Solid Tumors



11/10/2006 10:26:00 AM

PRAGUE, Czech Republic & TUCSON, Ariz.--(BUSINESS WIRE)--AmpliMed® today reported final results from the Phase I trial of its lead drug candidate, Amplimexon® (imexon for inj.), in patients with advanced solid tumors. The results are being presented by Tomislav Dragovich, MD, PhD, Assistant Professor of Medicine of the Arizona Cancer Center and lead investigator of the study, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held this week in Prague, Czech Republic.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES